Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Manufacturers Explore Shared Audits in Quest to Control Global Supply Chain

This article was originally published in The Gold Sheet

Executive Summary

Sharing audits could be the key to controlling the global supply chain, Rx-360 consortium members agreed at their first meeting this month. With suppliers inundated by audit requests in the wake of last year's heparin incident, many have started charging customers for hosting audits, they said. Shared audits are seen as cheaper and better. Rx-360-led audits prove the most popular of three proposed audit-sharing systems. The others involved sharing subscription audits or individual drug makers' audits, the least popular option. Rx-360 also would scan for emerging adulteration risks. Tiers 2 and 3 suppliers should be monitored too, Beroe says. Pfizer upgrades three key aspects of its supplier management program. Parexel, Novartis note stepped-up FDA enforcement with a new focus on supply chain management. Advice given on how to audit - and how not to.

You may also be interested in...



2020 In Review: Despite Pandemic, The US FDA Issued Just 20% Fewer Drug GMP Warning Letters

The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.

US FDA Still “Actively” Drafting Proposed Licensing Rule For Wholesalers and 3PLs

Pharmaceutical manufacturers should have already begun serializing products and verifying saleable returns to comply with DSCSA, says FDA official who also asserted that licensing standards for wholesale distributors and third-party logistics providers will be forthcoming. This rule is already six years overdue under a DSCSA mandated timeline.

US FDA Calls For Drugmakers To Test Alcohol Ingredients For Methanol

The US FDA wants manufacturers and compounding facilities to test drug products for methanol in alcohol ingredients, and responds to reports of fatal methanol poisonings of consumers who ingested alcohol-based based hand sanitizers.

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel